Iovance Biotherapeutics Inc IOVA

Leader in Global Drug Development of T Cell Therapies PHILADELPHIA, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced the appointment of Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer (CMO), effective September 30, 2026. “We are pleased to welcome Noah to Iovance as we pre

IOVA surged 77% and IBRX gained 11%, bucking biotech’s decline, while SLS fell 14% and VNDA slipped 7%.

The rallies were driven by expanding opportunities tied to biotechnology and artificial intelligence.

Iovance Biotherapeutics (NASDAQ:IOVA) saw its share price increase by 31.48 percent on Tuesday to finish at $14.45 apiece after raising its full-year revenue growth guidance by as much as 60 percent, thanks to the strong demand for its cancer treatments. In an updated report on the same day, the company said that it is now […]

Nvidia fell 0.7%, reversing from Monday’s gains, when it announced a $150 billion expansion to its stock buyback plan and software to tackle the problem of AI safety. Navitas Semiconductor closed flat, erasing earlier gains seen after it received a U.S. Army grant to develop power semiconductor technology. The company has faced a recent slump in its share price, navigating recent quarterly losses and a patent dispute with peer Wolfspeed.

Shares of Iovance Biotherapeutics surged Tuesday after the biotech company raised its fiscal-year revenue guidance, thanks to rising demand for a pair of melanoma treatments. Iovance stock rose 28% to $14.06, pacing toward its highest close since May 7, 2024, when shares reached $13.98, according to Dow Jones Market Data. Iovance raised its fiscal 2026 revenue guidance to between $410 million and $420 million, driven by strong U.S. demand for Amtagvi and Proleukin, the company said.

Iovance raised its 2026 revenue forecast due to strong U.S. demand for Amtagvi and Proleukin cancer therapies.

Iovance Biotherapeutics (NASDAQ:IOVA) raised its full-year 2026 total revenue guidance to between $410 million and $420 million, compared with its previous forecast of $350 million to $370 million. The midpoint of the revised range is $55 million above the midpoint of the previous guidance and represents an increase of approximately 15%.

Investing.com -- Shares of Iovance Biotherapeutics Inc (NASDAQ:IOVA) surged more than 14% in premarket trading Tuesday after the commercial-stage biotechnology company raised its full-year 2026 revenue outlook well above Wall Street expectations. Strong domestic adoption of its flagship tumor-infiltrating lymphocyte therapy, Amtagvi, alongside sustained sales of Proleukin, prompted management to boost its top-line target to between $410 million and $420 million.

New Guidance Represents an Increase of $55 Million at the Midpoint from the Prior Range of $350 to $370 Million Strong U.S. Demand for Amtagvi and Proleukin Drives Increased Outlook PHILADELPHIA, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today raised its full year 2026 total revenue gui